Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cheaper version of melanoma drug enters testing

NCT ID NCT07476326

Summary

This study aims to see if a new, potentially more affordable version of the cancer drug Opdivo (called Bmab1700) behaves similarly in the body. It will involve 120 adults whose melanoma has been completely removed by surgery. Participants will receive either the new drug or Opdivo to compare drug levels, safety, and how the immune system responds.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.